US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Yesterday's Top Gainers

743.74

-8.7574-1.16%

Number of Gainers:16

Number of Losers:36

Number of Flat:5

PE:- -

High:753.23

Open:752.57

Low:739.47

Close:752.49

Loading ...

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs

Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors

BiyaPay Analyst: US State Government to Include Bitcoin in Fiscal Bill, Solidifying Cryptocurrency's Potential as "Digital Gold"

ZCCM-IH Reappoints Bishop Mambo as Non-Executive Director

Volta Metals Advances Acquisition of Rare Earth Project in Ontario

Why Seanergy Maritime Holdings Corp (SHIP) Outpaced the Stock Market Today

SunCar Technology Reports 2024 Annual Results

Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025

CytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual Meeting

RELX plc Enhances Shareholder Value with Strategic Share Buyback

Piper says SpringWorks deal suggests Immunome’s varegacestat ‘undervalued’

ALL-NEW NORWEGIAN AQUA DEBUTS AS THE NEWEST SHIP IN PORT CANAVERAL FOR THE SPRING/SUMMER CRUISE SEASON

Why Is Cancer Drug Developer Revolution Medicines Stock Trading Higher On Monday?

GDS Holdings Files Annual Report, Reinforcing Transparency

Is RPC (RES) Stock Undervalued Right Now?

2 Cash-Heavy Stocks to Keep an Eye On and 1 to Brush Off

Houston American Energy Corp. Announces Results of Special Meeting of Stockholders

iRhythm Presents New Real-World Data on Ambulatory Cardiac Monitoring at HRS 2025 Reinforcing Clinical Superiority of Zio Long-Term Continuous Monitoring

Promising Penny Stocks To Watch In April 2025

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4563/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4563","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4563\",,,,,undefined,":{"symbol":"BK4563","market":"US","secType":"PLATE","nameCN":"Yesterday's Top Gainers","latestPrice":743.7364,"timestamp":1746647999999,"preClose":752.49384,"halted":0,"volume":74232277,"delay":0,"changeRate":-0.011638,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-8.757446,"latestTime":"05-07 16:00:00 EDT","open":752.5665,"high":753.2303,"low":739.47,"amount":805475516.601735,"amplitude":0.018286,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1746691200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":2.171428,"peRate":35.383469,"turnoverRate":0.013728,"increases":16,"decrements":36,"flats":3,"marketCap":132883736033,"floatMarketCap":70738261523.5},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4563\",,,,,undefined,":{"symbol":"BK4563","high":753.2303,"amplitude":0.018286,"preClose":752.49384,"low":739.47,"pbRate":"2.171428","latestPrice":743.7364,"volume":74232277,"delay":0,"open":752.5665,"prevYearClose":733.5465,"prevWeekClose":748.6267,"prevMonthClose":715.2634,"prevQuarterClose":750.7285,"fiveDayClose":715.2634,"twentyDayClose":604.665,"sixtyDayClose":769.1825,"secType":"PLATE","market":"US","turnoverRate":0.013728,"peRate":35.383469,"marketCap":132883736033,"floatMarketCap":70738261523.5,"timestamp":1746647999999,"nameCN":"Yesterday's Top Gainers"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4563\",,,,undefined,":{"bkCode":"BK4563","up":16,"down":36,"flat":5},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4563\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531782612","title":"Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2531782612","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531782612?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:30","pubTimestamp":1745926200,"startTime":"0","endTime":"0","summary":"“We look forward to sharing more about the potential of our modifier gene therapy platform and the meaningful results we are seeing in the clinic during these two important meetings for the retina community,” said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. “Ocugen remains on track to deliver on our commitment to file three Biologics License Applications/Marketing Authorization Applications  in the next three years—potentially addressing significant unmet medical need for large patient populations through our gene-agnostic approach.”Ocugen’s presence in Utah kicks off with the Company Showcase at Eyecelerator, presented by Dr. Huma Qamar, Chief Medical Officer at Ocugen, and continues through presentations and thought leadership engagement at ARVO.Session: Retina—Gene Therapy and Novel Mechanisms of Action ShowcaseLocation: Grand Hyatt Deer Valley,Strawberry Ballroom, Park City, UTDate: Friday, May 2, 2025Time: 2:06 p.m. MDTPresenter: Dr. Huma Qamar. Safety and Effic","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ocugen-present-modifier-gene-therapy-113000315.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4568","OCGN","BK4139","BK4563"],"gpt_icon":0},{"id":"2531781315","title":"Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2531781315","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531781315?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:00","pubTimestamp":1745924400,"startTime":"0","endTime":"0","summary":"– Total revenues of $1,053 million in the first quarter  ; total product revenues of $922 million in Q1'25 . – Jakafi  net product revenues of $709 million in Q1'25 ; increasing full year 2025 Jakafi guidance to a new range of $2,950 - $3,000 million from $2,925 - $2,975 million. – Opzelura  cream net product revenues of $119 million in Q1'25 . – Niktimvo  net product revenues of $14 million in the first two months of U.S. launch demonstrating strong commercial execution and high patient need. – New, 18-week data from ongoing Phase 3 study of povorcitinib in hidradenitis suppurativa  demonstrates continued improvement in HiSCR from Week 12 in addition to high response rates in placebo-crossover patients. – Positive Phase 2 topline results for povorcitinib in chronic spontaneous urticaria  demonstrates proof-of-concept in new indication. WILMINGTON, Del., April 29, 2025----Incyte  today reports 2025 first quarter financial results, and provides a status update on the Company’s clinical ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/incyte-reports-2025-first-quarter-110000860.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4144","BK4139","QD","IAI","PN","BK4581","BK4096","BK4503","BK4588","ET","BK4561","BK4550","INCY","BK4585","BK4532","BK4582","BK4094","BTC","BK4166","FL","BK4590","BK4563"],"gpt_icon":0},{"id":"2531665786","title":"Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2531665786","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531665786?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:00","pubTimestamp":1745924400,"startTime":"0","endTime":"0","summary":"“We are excited to explore a new avenue to treat cancers expressing FAP-α with [212Pb]PSV359,\" commented Markus Puhlmann, Chief Medical Officer of Perspective. \"FAP-α is expressed directly on certain tumors as well as on cells that form the stroma, a part of the tumor microenvironment, which also plays a role in disease progression and treatment outcome in additional solid tumors. This study aims to select a dose for [212Pb]PSV359 to advance as either a monotherapy or eventually in combination with other agents for future clinical development.\". Perspective is conducting a multi-center, open-label, dose-finding and dose-expansion study  of [212Pb]PSV359 in patients with advanced solid tumors that express FAP-α as determined by imaging with [203Pb]PSV359. The primary objective of the dose finding phase of the study is to assess the safety and tolerability of various doses of [212Pb]PSV359 in order to determine the recommended P","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/perspective-therapeutics-announces-first-patient-110000458.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0359202008.SGD","SG9999011746.SGD","BK4139","LU0359201612.USD","BK4531","IE00BYTNYN87.SGD","BK4552","LU1023057109.AUD","BK4509","TME","BK4526","LU2039709279.SGD","BK4563","IE00BYQNZ168.SGD","BK4535","CATX","01698","BK4108","BK4571","IE00B12V2V27.USD","BK4548","BK4565"],"gpt_icon":0},{"id":"2531606204","title":"BiyaPay Analyst: US State Government to Include Bitcoin in Fiscal Bill, Solidifying Cryptocurrency's Potential as \"Digital Gold\"","url":"https://stock-news.laohu8.com/highlight/detail?id=2531606204","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531606204?lang=en_us&edition=fundamental","pubTime":"2025-04-29 18:00","pubTimestamp":1745920800,"startTime":"0","endTime":"0","summary":"BlockBeats News, April 29th, the Arizona State Legislature passed the \"Bitcoin Strategic Reserve Bill\" (SB 1025 and SB 1373), becoming the first in the U.S. to promote Bitcoin's inclusion in its finan","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/291709","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["BK4601","MKR.USD.HKCC","IE0034235188.USD","BK4588","BK4594","LU1894683264.USD","BTC.USD.HKCC","LU0061475181.USD","MKR.USD.CC","09008","03439","03008","IE00B3QW5Z07.USD","03042","APT.USD.CC","BK4135","BK1611","TON.USD.CC","BK4585","BK4021","IE00BGHQF748.EUR","IE00B64PRP62.GBP","SB","TON.USD.HKCC","USD","09439","09042","USDT.USD.CC","STT","BTC.USD.CC","BK4563","83042","APT.USD.HKCC","LU1894683348.USD","LU1883839398.USD"],"gpt_icon":1},{"id":"2531278956","title":"ZCCM-IH Reappoints Bishop Mambo as Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2531278956","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531278956?lang=en_us&edition=fundamental","pubTime":"2025-04-29 15:57","pubTimestamp":1745913436,"startTime":"0","endTime":"0","summary":"An announcement from ZCCM Investments Holdings ( ($FR:MLZAM) ) is now available. ZCCM Investments Holdings PLC has announced the reappointment of B...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/zccm-ih-reappoints-bishop-mambo-as-non-executive-director?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/zccm-ih-reappoints-bishop-mambo-as-non-executive-director?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IH","BK4510","BK4563","BK4085"],"gpt_icon":0},{"id":"2531817293","title":"Volta Metals Advances Acquisition of Rare Earth Project in Ontario","url":"https://stock-news.laohu8.com/highlight/detail?id=2531817293","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531817293?lang=en_us&edition=fundamental","pubTime":"2025-04-29 06:37","pubTimestamp":1745879837,"startTime":"0","endTime":"0","summary":"An update from Cashbox Ventures Ltd ( ($TSE:VLTA) ) is now available. Volta Metals Ltd. has announced its satisfaction with due diligence on the Sp...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/volta-metals-advances-acquisition-of-rare-earth-project-in-ontario?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/volta-metals-advances-acquisition-of-rare-earth-project-in-ontario?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4214","BK4563","VLTA"],"gpt_icon":0},{"id":"2531729964","title":"Why Seanergy Maritime Holdings Corp (SHIP) Outpaced the Stock Market Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2531729964","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531729964?lang=en_us&edition=fundamental","pubTime":"2025-04-29 06:00","pubTimestamp":1745877617,"startTime":"0","endTime":"0","summary":"Seanergy Maritime Holdings Corp  closed the most recent trading day at $5.78, moving +0.87% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 0.06%. At the same time, the Dow added 0.28%, and the tech-heavy Nasdaq lost 0.1%.Coming into today, shares of the company had lost 13.71% in the past month. In that same time, the Transportation sector lost 8.4%, while the S&P 500 lost 4.29%.Analysts and investors alike will be keeping a close eye on the performance of Seanergy Maritime Holdings Corp in its upcoming earnings disclosure. In that report, analysts expect Seanergy Maritime Holdings Corp to post earnings of -$0.44 per share. This would mark a year-over-year decline of 177.19%. Meanwhile, the latest consensus estimate predicts the revenue to be $23.16 million, indicating a 39.51% decrease compared to the same quarter of the previous year.Want the latest recommendations from Zacks Investment Research?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-seanergy-maritime-holdings-corp-220017009.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4021","SHIP","BK4563"],"gpt_icon":0},{"id":"2531266232","title":"SunCar Technology Reports 2024 Annual Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2531266232","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531266232?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:30","pubTimestamp":1745872200,"startTime":"0","endTime":"0","summary":"NEW YORK, April 28, 2025 /PRNewswire/ -- SunCar Technology Group Inc.  , an innovative leader in cloud-based, software-focused B2B auto eInsurance and auto services in China, today reported annual financial results for the year ended December 31, 2024.Revenue for 2024 increased 21% to $441.9 million, compared to $363.7 million in 2023. Adjusted EBITDA for 2024 increased 492% to $9.8 million, compared to $1.6 million in 2023. Expanded collaboration with Tesla to 48 cities from an initial 6 at the start of the year. Initiated an innovative partnership with Xiaomi to offer customized insurance products. Secured a two-year agreement with SAIC Maxus, a leading commercial vehicle manufacturer, to enhance eInsurance management across its dealership network. Increased our collaboration with auto dealers, initially with Chang'an Deepal. We embedded our insurance systems into its dealers to enable the sale of new products. Established Anji AI Technology Service Center to co-develop insurance pro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/suncar-technology-reports-2024-annual-203000444.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/suncar-technology-reports-2024-annual-203000444.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4504","LU0052750758.USD","BK4531","BK4581","BK4574","BK4555","BK4534","BK4505","BK4099","BK4509","BK4585","BK4192","EVS.SI","BK4563","BK4532","SDA","NIO.SI","ZK","LU0708995583.HKD","LU0320764599.SGD","BK4526","SDAWW","BK4551","BK4503","BK4548","BK4588"],"gpt_icon":1},{"id":"2531661052","title":"Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531661052","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531661052?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:05","pubTimestamp":1745870700,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., April 28, 2025  -- Relay Therapeutics, Inc. , a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report first quarter 2025 financial results and corporate highlights after the U.S. financial markets close on Monday, May 5, 2025.Relay Therapeutics  is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Thera","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/relay-therapeutics-announce-first-quarter-200500451.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4563","BK4139","RLAY"],"gpt_icon":0},{"id":"2531125091","title":"CytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2531125091","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531125091?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:00","pubTimestamp":1745870400,"startTime":"0","endTime":"0","summary":"Novel engineering approach to developing an mRNA-encoded masked IL-12 therapeutic demonstrates potent anti-tumor activity with significantly enhanced tolerability. AboutCytomX Therapeutics, Inc.CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODYtherapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates , T-cell engagers, and immune modulators such as cytokines. CytomX’s clinical-stage pipeline includes CX-2051 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward epithelial cell adhesion molecule , armed with a topoisomerase-1 inhibitor payload. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cytomx-therapeutics-presents-preclinical-data-200000860.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4108","BK4531","SG9999011746.SGD","01698","BK4139","IE00BYQNZ168.SGD","LU2039709279.SGD","BK4571","IE00B12V2V27.USD","LU0359201612.USD","BK4548","LU0359202008.SGD","BK4552","BK4535","BK4563","IE00BYTNYN87.SGD","CTMX","TME","LU1023057109.AUD","BK4565","BK4509","BK4526"],"gpt_icon":0},{"id":"2531237963","title":"RELX plc Enhances Shareholder Value with Strategic Share Buyback","url":"https://stock-news.laohu8.com/highlight/detail?id=2531237963","media":"TIPRANKS","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531237963?lang=en_us&edition=fundamental","pubTime":"2025-04-29 00:22","pubTimestamp":1745857350,"startTime":"0","endTime":"0","summary":"RELX plc ( ($GB:REL) ) has shared an update. RELX plc announced the purchase of 211,500 of its own ordinary shares through ABN AMRO Bank N.V. on th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/relx-plc-enhances-shareholder-value-with-strategic-share-buyback-4?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/relx-plc-enhances-shareholder-value-with-strategic-share-buyback-4?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4526","BK4075","BK4551","BK4563","RLX"],"gpt_icon":0},{"id":"2530236893","title":"Piper says SpringWorks deal suggests Immunome’s varegacestat ‘undervalued’","url":"https://stock-news.laohu8.com/highlight/detail?id=2530236893","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530236893?lang=en_us&edition=fundamental","pubTime":"2025-04-28 23:20","pubTimestamp":1745853606,"startTime":"0","endTime":"0","summary":"After SpringWorks Therapeutics (SWTX) and Merck KGaA (MKGAY) announced the companies have entered into a definitive agreement for Merck KGaA to acq...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/piper-says-springworks-deal-suggests-immunomes-varegacestat-undervalued?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/piper-says-springworks-deal-suggests-immunomes-varegacestat-undervalued?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMNM","BK4563","BK4139","SWTX"],"gpt_icon":0},{"id":"2531255820","title":"ALL-NEW NORWEGIAN AQUA DEBUTS AS THE NEWEST SHIP IN PORT CANAVERAL FOR THE SPRING/SUMMER CRUISE SEASON","url":"https://stock-news.laohu8.com/highlight/detail?id=2531255820","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531255820?lang=en_us&edition=fundamental","pubTime":"2025-04-28 23:10","pubTimestamp":1745853000,"startTime":"0","endTime":"0","summary":"– Norwegian Aqua is Sailing Seven-Day Fun-in-the-Sun Caribbean Voyages Now Through August 2025, Including Visits to Great Stirrup Cay, NCL's Private Island Destination in the Bahamas –。– Norwegian Cruise Line's Newest Ship Features the Growing Viral Sensation the Aqua Slidecoaster – the World's First Hybrid Roller Coaster and Waterslide – and MORE Innovative Experiences for the Whole Family –。– For B-roll and Additional Assets of Norwegian Aqua, Please Visit thePress Kit Here–。MIAMI, April 28, 2025 /PRNewswire/ -- Norwegian Cruise Line, the innovator in global cruise travel, celebrated the debut of the all-new Norwegian Aquato Port Canaveral, Fla. on Saturday, April 26, 2025, where she commenced her inaugural season of round-trip Caribbean cruises as the newest ship in port.Norwegian Aqua boasts many first-in-the-industry activities including the hallmark top-deck attraction, The Aqua Slidecoaster. The world's first-ever hybrid waterslide and roller coaster continues to generate growin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/norwegian-aqua-debuts-newest-ship-151000806.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/norwegian-aqua-debuts-newest-ship-151000806.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SHIP","NCL","BK4533","BK4107","LU2041044095.USD","BK4588","LU1983260115.SGD","BK4142","BK4585","BK4161","BK4517","PORT","LU2355687059.USD","AQUA","NCLH","FOR","LU2092937221.SGD","BK4086","LU0985320562.USD","LU1571399168.USD","BK4021","LU1699723380.USD","BK4563","BK4024","ALL"],"gpt_icon":0},{"id":"2530069233","title":"Why Is Cancer Drug Developer Revolution Medicines Stock Trading Higher On Monday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2530069233","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530069233?lang=en_us&edition=fundamental","pubTime":"2025-04-28 23:02","pubTimestamp":1745852567,"startTime":"0","endTime":"0","summary":"\"These data reinforce the clinical potential of zoldonrasib following the initial tolerability and antitumor activity reported late last year in patients with pancreatic ductal adenocarcinoma,\" said Mark A. Goldsmith, CEO and chairman of Revolution Medicines. \"Together these results support further evaluation of zoldonrasib as monotherapy and in combination as we continue efforts to advance innovative targeted medicines for patients living with these hard-to-treat cancers,\" Goldsmith commented.RMC-9805-001 is a multicenter, open-label, dose-escalation and dose-expansion Phase 1 study designed to evaluate zoldonrasib in patients with advanced solid tumors harboring a KRAS G12D mutation.As of December 2, 2024, the data cutoff date, 90 solid tumor patients were treated with 1200 mg once daily , the candidate's recommended Phase 2 dose.In these patients, zoldonrasib demonstrated an acceptable safety profile that was generally consistent with previously reported data for this compound in pa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-cancer-drug-developer-revolution-150247153.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0348723411.USD","QD","LU1861215975.USD","BK4503","LU1861220033.SGD","LU0124384867.USD","LU0724618433.USD","LU1720051017.SGD","IE00BZ199S13.USD","BK4512","BK4588","RVMDW","IE00BD6J9T35.USD","BK4605","LU1861214812.USD","MDCO","BK4585","LU1854104046.USD","LU1978683503.SGD","RVMD","LU1548497426.USD","BK4139","BK4166","BK4141","LU1854103824.USD","LU2360107325.USD","ON","LU2298322129.HKD","LU2357305700.SGD","LU1720051108.HKD","LU1861219969.SGD","BK4563"],"gpt_icon":0},{"id":"2530284074","title":"GDS Holdings Files Annual Report, Reinforcing Transparency","url":"https://stock-news.laohu8.com/highlight/detail?id=2530284074","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530284074?lang=en_us&edition=fundamental","pubTime":"2025-04-28 22:13","pubTimestamp":1745849596,"startTime":"0","endTime":"0","summary":"The latest update is out from GDS Holdings Ltd. ( ($HK:9698) ). GDS Holdings Limited announced the filing of its annual report on Form 20-F for the...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gds-holdings-files-annual-report-reinforcing-transparency?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gds-holdings-files-annual-report-reinforcing-transparency?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4505","BK4614","BK4588","BK4607","BK4526","BK4116","GDS","BK4563","BK4529","BK4531"],"gpt_icon":0},{"id":"2531258064","title":"Is RPC (RES) Stock Undervalued Right Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2531258064","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531258064?lang=en_us&edition=fundamental","pubTime":"2025-04-28 21:40","pubTimestamp":1745847614,"startTime":"0","endTime":"0","summary":"The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.One stock to keep an eye on is RPC . RES is currently holding a Zacks Rank of #2  and a Value grade of A.Finally, investors should note that RES has a P/CF ratio of 4.77. This metric focuses on a firm's operating cash flow and is often used to find stocks that are undervalued based on the strength of their cash outlook. RES's current P/CF looks attractive when compared to its industry's average P/CF of 5.90. RES's P/CF has been as high as 6.73 and as low as 4.13, with a median of 5.50, all within the past year.These are only a few of the key metrics included in RPC's strong Value grade, but they help show that the stock is likely undervalued right now. When factoring in the strength of its earnings outlook, RES loo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rpc-res-stock-undervalued-now-134014842.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4179","RES","BK4563"],"gpt_icon":0},{"id":"2530281984","title":"2 Cash-Heavy Stocks to Keep an Eye On and 1 to Brush Off","url":"https://stock-news.laohu8.com/highlight/detail?id=2530281984","media":"StockStory","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530281984?lang=en_us&edition=fundamental","pubTime":"2025-04-28 21:09","pubTimestamp":1745845742,"startTime":"0","endTime":"0","summary":"Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.Not all businesses with cash are winners, and that’s why we built StockStory - to help you separate the good from the bad. Keeping that in mind, here are two companies with net cash positions that can continue growing sustainably and one that may struggle.Founded by two individuals involved in the development of leading procurement software Ariba, Guidewire  offers insurance companies a software-as-a-service platform to help sell their products and manage their workflows.Annual revenue growth of 12.4% over the last three years was below our standards for the software sector. Gross margin of 61.4% is below its competitors, leaving less money to invest in areas like marketing and R&D. Customer acquisition costs take a while to recoup, making it difficult to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/2-cash-heavy-stocks-keep-130902576.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4106","BK4563","TOST","GWRE","BK4608","BK4157","NSSC","BK4585","BK4588","BK4023","BK4227"],"gpt_icon":0},{"id":"2530040007","title":"Houston American Energy Corp. Announces Results of Special Meeting of Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2530040007","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530040007?lang=en_us&edition=fundamental","pubTime":"2025-04-28 21:00","pubTimestamp":1745845200,"startTime":"0","endTime":"0","summary":"HOUSTON, TX, April 28, 2025  -- Houston American Energy Corp.  , today announced the results of the Company’s special meeting of stockholders  held virtually on April 24, 2025.At the Meeting, all of the matters put forward before the Company’s stockholders for consideration and approval, as set out in the Company’s definitive proxy statement dated April 11, 2025, were approved by the requisite number of votes cast at the meeting.Of most importance, the HUSA shareholders approved the Company’s proposed acquisition of AbundiaGlobal Impact Group  with over 90% of shareholders’ votes cast supporting HUSA’s plan to acquire AGIG, a company specializing in converting waste into high value fuels and chemicals. The acquisition supports HUSA’s strategy to diversify its portfolio, expand its global footprint and execute its strategy aimed at driving shareholder value through innovation in the renewable energy sector.HUSA and AGIG will continue developing a structured integration and execution pla","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/houston-american-energy-corp-announces-130000359.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HUSA","BK4563","BK4213"],"gpt_icon":0},{"id":"2530409743","title":"iRhythm Presents New Real-World Data on Ambulatory Cardiac Monitoring at HRS 2025 Reinforcing Clinical Superiority of Zio Long-Term Continuous Monitoring","url":"https://stock-news.laohu8.com/highlight/detail?id=2530409743","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530409743?lang=en_us&edition=fundamental","pubTime":"2025-04-28 20:05","pubTimestamp":1745841900,"startTime":"0","endTime":"0","summary":"Findings in a younger, commercially insured population build on Medicare-based CAMELOT results, expanding the generalizability of Zio LTCM's clinical impact across patient groups.Latest data showed Zio LTCM was associated with higher diagnostic yield and lower likelihood of repeat testing and cardiovascular events compared to all other LTCM products.SAN FRANCISCO, April 28, 2025  -- iRhythm Technologies, Inc.  announced results from a large real-world retrospective analysis presented at the Heart Rhythm Society’s annual meeting, HRS2025, held April 24–27 in San Diego, CA, The Assessment of Variation in AmbuLatory Cardiac MONitoring: Real-World Evidence of Commercially Insured Beneficiaries  study—drawing on claims data from a cohort of 428,707 commercially insured patients—represents the largest real-world comparative evaluation of ambulatory cardiac monitoring  among this population to date, and reinforces the clinical superiority of the Zio long-term continuous monitoring  service.“O","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/irhythm-presents-real-world-data-120500535.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0498741114.HKD","LU1169589451.USD","BK4017","LU1223083913.SGD","AEM","SG9999001143.SGD","BK4082","LU1169590202.USD","LU2308191902.HKD","LU1223082196.USD","BK4129","IRTC","LU0496367417.USD","BK4563","LU0498741890.SGD","BK4585","BK4080","SRC","MI","ACM","BK4516","BK4077","BK4231"],"gpt_icon":0},{"id":"2530401343","title":"Promising Penny Stocks To Watch In April 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2530401343","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530401343?lang=en_us&edition=fundamental","pubTime":"2025-04-28 20:05","pubTimestamp":1745841900,"startTime":"0","endTime":"0","summary":"Over the last 7 days, the United States market has risen by 7.0%, reflecting a positive trend with a 12-month increase of 7.5% and an anticipated annual earnings growth of 14%. While penny stocks might seem like a relic from past market eras, they continue to represent smaller or newer companies that offer affordability and growth potential. By focusing on those with robust financials and clear growth trajectories, investors can find promising opportunities in this sector.Overview: Nano Dimension Ltd., along with its subsidiaries, provides additive manufacturing solutions both in Israel and internationally, with a market cap of approximately $361.74 million.Overview: SelectQuote, Inc. operates a technology-enabled, direct-to-consumer distribution platform for selling insurance policies and healthcare services in the United States, with a market cap of approximately $566.35 million.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/promising-penny-stocks-watch-april-120500185.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4170","SB","BK4021","BK4526","BABB","BK4161","BK4179","TTI","BK4563","BK4023","BK4546","NNDM","SLQT","TUYA","BK4173","BK4505","BK4509","BK4209"],"gpt_icon":0}],"pageSize":20,"totalPage":11,"pageCount":8,"totalSize":208,"code":"91000000","status":"200"}]}}